09/07/2026
In "Frontiers in Oncology", Dr. Katherine Hobbing and colleagues report that 'Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer', and is dedicated to "the memories of Dr. Katie Hobbing, who had to leave the party way too soon".